Andre Goy, MD, Chairman, John Theurer Cancer Center, Part of @HackensackUMC discusses the three-year survival analysis of the ZUMA-1 study investigating axicabtagene ciloleucel in diffuse large b-cell lymphoma (DLBCL) presented at ASH 2019.
Advertisement